Using a Randomised Control Trial to study the impact of Newcastle Disease vaccine on poultry farmer welfare and livelihoods

In 2020, Oxford Policy Management (OPM) was contracted by GALVmed to implement an intervention and conduct an associated impact study on the adoption of a Newcastle Disease Vaccine (NDV) by small-scale poultry farmers in rural Tanzania in the districts of Chemba and Mbozi. The objective of the study is to quantify the causal effects that the delivery of NDV has on the “production, productivity, and livelihoods of small-scale producers (SSPs)”. The study involves two main activities:

  1. The design and implementation of an NDV intervention in selected SSP farming areas of Tanzania.
  2. The design and implementation of an experimental study to quantify the causal effects of the NDV intervention.

The impact study was designed as a randomised controlled trial (RCT) where the study sample was randomly split into one treatment group and one control group. The treatment group was offered and will continue to be offered the NDV intervention package. This group will be compared with a control group, who did not and will not receive the intervention package during the study. The control group will receive one round of the intervention after the study’s endline survey.

A baseline study was conducted between September and November 2021 and the endline survey is scheduled for September to November 2023. Further details on the RCT and its findings will be made available upon publication of the results.

Blog written by Lamyaa Al-Riyami

GALVmed discusses impact

Impact is an important topic for any philanthropic organisation and GALVmed is putting this topic front and centre of our agenda for 2022. The primary reason is that we are in the process of finalising and beginning to implement our ten-year strategy, and it is vitally important that we integrate the lessons we have learned so far and align on the topic of impact.

To kickstart this process, three workshops were held over the end of January and beginning of February 2022 with the aim to provide a common, organisational understanding of impact. We took a look at our record of impact and discussed some of the associated key lessons learned from the three main programmes GALVmed has delivered to date, namely the first and second Protecting Livestock, Saving Human Life programmes (PLSHL 1 and PLSHL 2), and the Veterinary Innovations Transforming Animal Health and Livelihoods programme (VITAL). These workshops constituted the first phase of a collective look at impact within the organisation.

A second phase is being led by the evaluation team, which operates under the Commercial Development and Impact department (CD&I) at GALVmed. Lasting eight weeks, the primary purpose is to collate further data, present findings to our donors and board, and most importantly, to implement actionable findings into the Commercial Development, Research and Development, Evaluation, and Enabling Environment programmes under the new strategy.

The key activities include taking lessons learned from previous programmes of work and considering the implications for new GALVmed projects and programmes, creating a theory of change for GALVmed at an organisational level, in which the GALVmed mission is clearly stated and pathways to impact explained, and linking impact to GALVmed’s overall assessment of organisational performance. Through this process we intend to identify our potential for impact in the new strategy as well as the key levers and drivers for change.

This blog was written by Katharine Tjasink